Introduction
Widespread uptake of revascularization by (primary) percutaneous coronary intervention (PCI) and pharmacological development has improved mortality and morbidity in acute coronary syndrome patients (ACS) patients. 1, 2 The European Society of Cardiology (ESC) recommends aspirin, statins, P2Y12 inhibitors, beta-blockers, and angiotensin converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARB), often referred to as optimal medical therapy (OMT), in patients with ST-elevation myocardial infarction (STEMI) or non-ST-elevation myocardial infarction (NSTEMI). The early versions of the European Society Cardiology (ESC) guidelines contain a Class I, Level A recommendation for aspirin, P2Y12 inhibitors, and statins in all ACS patients. 3, 4 Later in 2011 (NSTEMI) and 2012 (STEMI), this level of recommendation for beta-blockers and ACEi/ARBs only remained for patients with heart failure (HF) or left ventricular systolic dysfunction (LVSD). 5, 6 In EUROASPIRE IV adherence to recommended medication was suboptimal but improved over time; however, the combined effect of OMT medication was not studied. 7 To our knowledge studies on OMT prescription post-ACS, as well as its relation to temporal mortality trends in the real world, remain underreported. In this study, we investigated OMT prescription in an unselected ACS population from a Dutch tertiary hospital and mortality trends up to 1 year during almost a decade.
Methods

Study population and treatment
From 2006 until 2014, we prospectively recorded all consecutive patients diagnosed with STEMI or NSTEMI admitted to a non-academic hospital with primary PCI and coronary artery bypass grafting (CABG) facilities (Isala Klinieken, Zwolle, The Netherlands). ST-elevation myocardial infarction was diagnosed in patients presenting with ongoing chest pain suspected for ACS and electrocardiographic signs of STEMI [ST-segment elevation >2 mm in two contiguous precordial leads, >1 mm in two contiguous limb leads or new left bundle branch block on the electrocardiogram (ECG)]. Non-ST-elevation myocardial infarction was diagnosed if patients had angina in presence elevated cardiac troponin indicating myocardial necrosis without notable ECG-changes, or with ST-T wave changes associated with NSTEMI [(transient) ST-segment depression >1 mm, T-wave inversion, flat T-waves, T-wave pseudonormalization]. Emergency coronary angiography on arrival was the preferred treatment in STEMI patients. If indicated, subsequent revascularization by primary PCI or CABG was performed. Patients diagnosed with NSTEMI were treated according to the recent ESC guidelines available at the time. 4, 6 Before angiography, patients were pre-treated with aspirin, heparin, and a P2Y12 inhibitor (clopidogrel 600 mg or ticagrelor 180 mg loading dose).
Other pharmacological therapy was in accordance with ESC recommendations applicable at that time. [4] [5] [6] 8 There were no exclusion criteria.
Data collection
We used data from a single-centre observational registry. During hospitalization, information on baseline characteristics, risk factors, medical history, procedural features, and medical therapy were prospectively collected. We obtained discharge medication prescriptions listed in medical records. Thirty-day and 1-year follow-up regarding medication use was collected from outpatient records or by routine patient telephonic followup. Vital status was obtained from the Dutch national population registry as part of routine care. An independent Clinical Research Organisation managed the data [Diagram B.V. (Zwolle, the Netherlands)]. According to Dutch law written informed consent was not necessary.
Definitions
Optimal medical therapy was defined as a combination of aspirin, P2Y12 inhibitor, statin, beta-blocker, and ACEi/ARB, based on the ESC recommendations from the ESC published during the study period. [4] [5] [6] 8 Dual antiplatelet therapy (DAPT) was defined as the combination of aspirin and a P2Y12 inhibitor (clopidogrel, ticagrelor, or prasugrel). We defined OMT including oral anticoagulation (OAC) and single antiplatelet therapy (SAPT) (OMT including OAC þ SAPT) as a combination of OAC and SAPT (either aspirin or a P2Y12 inhibitor) or DAPT without OAC in addition to statins, beta-blockers, and an ACEi/ARB.
Prescription and outcome measures
The main prescription measures were OMT prescription and prescription of at least DAPT and a statin at discharge, 30 days, and 1 year. We used all-cause and cardiac mortality as our outcome measures. Cardiac mortality was defined as death from an established cardiac cause or death of which the underlying cause could not be established. In-hospital mortality was defined as established death during hospitalization, or death < _7 days after admission if death after discharge for the index ACS could not be unequivocally established.
Statistical analysis
Continuous variables are presented by means (standard deviation) for normal distributions or medians (interquartile range) for non-normal distributions. Categorical variables are presented as absolute numbers and proportions. Differences were examined with the independent t or Mann-Whitney U tests, as indicated. We used the v 2 or Fisher's exact test for categorical variables. We used the linear-by-linear association test to assess temporal time trends. We used McNemar's or Cochran's Q-test to determine differences between paired variables. We used the Kaplan-Meier analysis to establish crude 1-year mortality estimates. Coxregression was used to obtain crude and adjusted hazard ratios (HR) and 95% confidence intervals (95% CI) and to assess the association of OMT prescription at discharge and 1-year mortality in survivors of hospitalization. We composed a model with variables that were associated with 1-year mortality, or OMT prescription at discharge. The model included age, gender, diagnosis STEMI, preadmission medication (aspirin, statin, beta-blockers, ACEi/ARB, P2Y12 inhibitor, OAC), diabetes, hypertension, previous myocardial infarction (MI), previous stroke, shock during acute phase, glomerular filtration rate < 60 mL/min/1.73 m 2 , PCI during hospitalization, OAC at discharge, systolic blood pressure and heart rate at discharge. We performed a sensitivity analyses in patients with known left ventricular ejection fraction (LVEF) at discharge focused on patients with an IA indication for beta-blockers and ACEi/ARBs (i.e. LVEF < _ 40%).
9,10 Additionally, we performed a sensitivity analysis in patients on OMT including OAC þ SAPT at discharge. In order to assess potential confounding by indication, we performed sensitivity analyses with a Cox-regression model that adjusted for independent predictors of OMT prescription at discharge as well as model that adjusted for the predicted probability of OMT prescription at discharge. A P-value of <0.05 was considered statistically significant. All analysis were performed using SPSS version 24.0 (SPSS Inc., Chicago, IL, USA).
Results
Study population and baseline characteristics
During 9 years, a total of 9202 consecutive patients were included. The mean age was 65.7 years and 29.9% of patients were women ( 
Medication
Prescription was known in 91.1% of patients alive at discharge, 77.5% at 30 days, and 58.7% at 1 year ( Table 2) . At discharge, prescription was highest for beta-blockers (88.0%) and aspirin (87.3%). Thirty-day prescription increased for statin, beta-blocker, ACEi/ARBs, and OAC. At 1-year, prescription of all drugs decreased. Among patients with LVEF < _ 40%, prescription of ACEi/ARB was significantly higher (P < 0.001). Prescription of beta-blockers at discharge and 30 days was >85%, irrespective of LVEF. However, 1 year post-ACS betablocker prescription was significantly higher among LVEF < _ 40% patients.
Medication combinations
At discharge 43.7% of patients were on OMT and 66.5% on at least DAPT and a statin ( Table 3) . At 30-days, the prescription of at least DAPT and statin decreased, but prescription of OMT increased (64.2% and 46.6%, respectively). Overall, prescription of at least DAPT and statin decreased 1 year after admission. In STEMI patients, prescription of OMT was higher at 30 days compared to discharge, (52.9% vs. 49.2%, P < 0.001), whereas in NSTEMI patients OMT prescription remained similar at discharge and 30 days (34.5% vs. 36.6%, P = 0.469). Irrespective of LVEF, OMT prescription significantly decreased 1 year post-ACS. Overall, prescription of at least DAPT or OAC þ SAPT and a statin at discharge, 30-days, and 1-year was 70.6%, 70.8%, and 44.6%, respectively, and 46.6%, 51.4%, and 29.4% for OMT including those on OAC þ SAPT.
Beta-blockers and angiotensin converting enzyme inhibitors or angiotensin receptor blockers and IA indications
Among patients with a known IA indication for both beta-blockers and ACEi/ARBs (i.e. LVEF < _ 40%) at discharge, co-prescription of at least beta-blockers and ACEi/ARBS was 66.0%. Optimal medical therapy prescription at discharge was 41.6% in patients with a known IA indication for beta-blockers and ACEi/ARBs ( Table 3) .
Medication trends
From 2006 until 2014 the overall prescription of statin, ACEi/ARB, and OAC at discharge significantly increased, whereas aspirin at discharge decreased ( Figure 1 ). Only the overall prescription of ACEi/ ARB at 30 days significantly increased. There were no significant trends in the overall prescription 1 year post-ACS. From 2008 until 2014, the overall OMT prescription at 30 days was higher than at discharge ( Figure 2 however, combined prescription of at least DAPT and statin at 1-year significantly increased (P = 0.023).
Mortality trends
There were no significant changes in all-cause and cardiac in-hospital, 30-day, and 1-year mortality during the study period ( Figure 3 and Supplementary material online, Table S2 ).
Optimal medical therapy and outcome
In a Cox-regression analysis to determine the relation between OMT prescription at discharge and 1-year all-cause mortality Table 4) . We performed additional sensitivity analyses to assess potential confounding by indication (Supplementary material online, Table S4 ). There were marginal differences in the adjusted HRs for 1-mortality compared to adjustment for independent predictors of OMT prescription at discharge 
Trends in survivors of hospitalization
There was a significant decrease in 1-year mortality among survivors of the index ACS hospitalization (P < 0.001) (Figure 4) . This decreasing trend was also observed in patients without OMT at discharge (P < 0.001), but not in patients on OMT at discharge (P = 0.143).
Discussion
This study presents an evaluation of real-world OMT prescription and mortality outcomes in a single-centre observational registry with >9000 ACS patients in the Netherlands between 2006 and 2014. There are five main observations. First, OMT prescription and mortality remained stable from 2006 until 2014. Second, 43.7% of the patients were discharged on OMT after an ACS admission. At 1 year, only 25.5% of patients were on OMT. Third, OMT prescription was lower among NSTEMI patients. Fourth, there was an overall decreasing trend in 1-year mortality among survivors of ACS hospitalization. This trend was apparent in patients without OMT, but not in those on OMT at discharge. Finally, among survivors of ACS hospitalization, OMT prescription at discharge was associated with a reduction in 1-year mortality after adjustment for variables associated with 1-year mortality and OMT at discharge. This association was no longer present after adjustment in a subset of patients with available LVEF at discharge.
Our findings indicate that from 2006 until 2014, OMT prescription post-ACS did not change, while simultaneously mortality outcomes remained stable. In the recent report of STEMI patients in SWEDEHEART, there was a dramatic reduction in mortality between 1995 and 2008, alongside the implementation of primary PCI and uptake pharmacological developments. Similar to our results, mortality outcomes plateaued between 2008 and 2014, while use of guideline-recommended drugs flattened at 70-90%. 2 Use of discharge medication was higher in SWEDEHEART. However, our study included both STEMI and NSTEMI patients and showed significantly lower prescription rates among NSTEMI patients. Furthermore, the Zwolle Myocardial Infarction Study Group was one of the early adaptors of (primary) PCI in STEMI patients, 11 which could be an advantage in gaining experience. This early experience and the high rates of (primary) PCI (85.5%) observed in our study, could explain the already flattening mortality rates starting in 2006. In SWEDEHEART, on the other hand plateauing mortality outcomes and PCI rates >80% do not appear until 2008. Overall, angiography and PCI performance in our study were high, 92.9% and 75.6%, respectively. This can be explained by (i) the high proportion of STEMI patients in our cohort, and (ii) the high rates of angiography and PCI in NSTEMI patients. Presumably, the latter is due to selection of NSTEMI patients presenting at non-PCI centres who are referred to our centre for angiography and PCI.
Compared to other registries from the early 2000s, our results suggest that prescription of discharge medication has improved. In the REACH registry (2003) (2004) ) use of aspirin (76%), statins (76%), and beta-blockers (63%) was lower compared to our results (aspirin: 87%, statins: 85%, and beta-blockers: 88%). 12 Medication use observed in secondary prevention registries from SWEDEHEART (2005 SWEDEHEART ( -2010 , and EUROASPIRE IV (2012-2013) was slightly higher (aspirin: 93% and 98%, statin: 90% and 9%, beta-blocker: 90% and 86%, ACEi/ARB: 73% and 77%). 7, 13 Even higher rates were observed in the STABILITY study (2008) (2009) (2010) (2011) (2012) (2013) , with higher discharge rates for aspirin (96%), statins (97%), and ACEi/ARBs (77%) with the 14 Yet, the lower aspirin prescription found in our study could be related to higher rates of OAC prescription compared to STABILITY (12% vs. 6%). Importantly, STABILITY was a randomized trial that reported back the investigators' prescription rates in proportion to the overall trial, this likely led to better adherence. We observed decreasing OMT prescription rates during the first year after ACS admission. Previously, results from the SYNTAX study showed an association between long-term OMT use an improved outcomes at 5-years, emphasizing the benefit of OMT. 15 However, long-term adherence is a challenge. Only 60% of patients discharged on aspirin, beta-blockers and statins still use these drugs at 1 month and 31% of ACS patients have stopped at least one of the OMT drugs after 6 months. 16, 17 Solutions to overcome non-adherence such as electronic pill bottles and financial rewards failed to improve adherence and clinical outcomes. 18 A polypill with guidelinerecommended drugs increased adherence rates up to 70-85%, yet large studies are warranted assess its effect on outcomes. 19 It remains important that physicians, or specialized nurses routinely check drug adherence, optimal dosing, and side-effects in order to maintain longterm adherence. Despite similar recommendations for both STEMI and NSTEMI, our study showed worse drug prescription among NSTEMI patients. Non-ST-elevation myocardial infarction patients in our study represent a higher risk population, which suggests a treatment gap. This problem has previously been attributed to underestimation of risk and treatment benefit in NSTEMI patients. [20] [21] [22] In CRUSADE, guidelines-recommended treatment (including OMT) was associated with improved 3-year mortality outcomes in NSTEMI patients. 23 Thus, it is paramount to optimally treat NSTEMI patients in accordance to the guidelines. From 2006 until 2014, major guideline adjustments focused on high-intensity statins and novel P2Y12 inhibitors. Additionally, guidelines proposed multiple alternatives for 'triple therapy' in patients with an indication for OAC. Triple or dual therapy consisting of OAC with DAPT or aspirin/P2Y12inhibitor for variable durations is an option based on ischaemic and bleeding risk. Furthermore there The Cox-regression model adjusted for the following variables: age, gender, diagnosis STEMI, preadmission medication (aspirin, statin, beta-blockers, ACEi/ARB, P2Y12 inhibitor, OAC), diabetes, hypertension, previous myocardial infarction, previous stroke, shock during acute phase, estimated glomerular filtration rate < 60 mL/min/1.73 m 2 , PCI during hospitalization, OAC at discharge, systolic blood pressure at discharge, and heart rate at discharge. 4 In 2011, the NSTE-ACS recommendation for betablockers remained unchanged (Class I, Level A in LVEF < 40%) but were changed for ACEi/ARBs (Class I, Level B). 6 The 2015 guidelines did not change for beta-blockers (Class I, Level A in LVEF < 40%), but were upgraded for ACEi/ARBs (Class I, Level A for LVEF < 40%, diabetes, and hypertension). 10 In retrospect, in 2006 there was a firmer indication for beta-blockers and ACEi/ARBs, whereas later during the study period guidelines allowed a more liberal approach to betablockers and ACEi/ARBs prescription in ACS patients. Nevertheless, our results do not show a clear reduction in prescription of OMT, beta-blockers, or ACEi/ARBs post-ACS during the complete study period; however, a slight decrease in prescription of OMT, betablocker, or ACEi/ARB between 2012 and 2014 could be related to implementation the 2011 and 2012 guideline updates. In our study, LVEF at discharge was known in 40.5% of the patients. Of this patients subset, approximately half of the patients had a LVEF > 40%. This category of patients may theoretically be optimally managed with just DAPT and a statin. The recommendation for ACEi/ARBs in ACS patients without LVEF < 40% or HF, is largely based on the combined result of the HOPE, PEACE, and EUROPA trials. 24 On the other hand, the recommendation of beta-blockers in ACS patients is based on evidence from the pre-PCI era. Contemporary registries from the PCI era have questioned the benefit of long-term beta-blocker use on mortality outcomes in ACS patients without HF or LVSD. 25, 26 Furthermore, in a large registry of >90 000 Medicare beneficiaries with ACS, patients adherent to statin, beta-blocker, ACEi/ARB had similar mortality rates compared to patients adherent to statins and ACEi/ARBs. 27 The role of betablockers and ACEi/ARBs in ACS patients with preserved LVEF should preferably be investigated in a contemporary randomized trial.
We observed an association between OMT at discharge and mortality. There might be several explanations for this. First, the prescription OMT at discharge might result in reduced mortality. Even after adjustment for possible confounders in sensitivity analyses with multiple models, we could not demonstrate confounding by indication. However, we might not have been able to correct for unmeasured residual confounding. Notably, OMT at discharge was not associated with improved outcomes in patients with available LVEF, including those with reduced LVEF. This conflicting result could be caused by selection of patients with available LVEF in this registry. Second, patients who receive OMT at discharge were generally lower risk (younger, less comorbidities) and thus may have a lower a priori risk of mortality the first year post-ACS. Third, patients with large MIs and an indication for OMT at discharge might have died before discharge from the hospital, resulting in a lower mortality in the OMT group. Further research should focus on the composition of 'OMT' and the comparison of OMT in a randomized setting.
Our study has several limitations. First, this study reflects the outcome of a single institution, and therefore caution is necessary when generalizing to a larger population.
Second, medication follow-up decreased during follow-up and may have influenced the association between OMT prescription and mortality. Third, our data reports prescriptions listed in medical records or reported by patients. We did not measure medication adherence derived from claims data or pill counts. Fourth, information on optimal dosing, contraindication, and reasons for discontinuation were not included. Fifth, we could not account for additional secondary prevention measures such as blood pressure control, glucose monitoring, smoking cessation, cardiac rehabilitation, and other life-style changes. Sixth, LVEF is an important factor related to OMT prescription and unfortunately was not available in all patients. Finally, although we used multivariate analysis to adjust for confounding and applied additional sensitivity analyses to assess for confounding by indication, we could not adjust for residual confounding by information that was not recorded in this study.
In conclusion, in this single-centre observational study with >9000 patients reflecting almost a decade of ACS care, <50% of patients were on OMT at discharge. Optimal medical therapy prescription and mortality outcomes did not change during the study period. Optimal medical therapy use at discharge was associated with a reduction in 1-year mortality. Further randomized studies are warranted to determine the role of beta-blockers and ACEi/ARBs in ACS patients with preserved LVEF.
